{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:41:34Z","timestamp":1761100894231},"reference-count":36,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2007,6,2]],"date-time":"2007-06-02T00:00:00Z","timestamp":1180742400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2007,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background: <\/jats:bold> Vinorelbine and gemcitabine have demonstrable single\u2010agent activity against lymphoma, show differing toxicity profiles and can be given in an outpatient setting.<\/jats:p><jats:p><jats:bold>Aims: <\/jats:bold> We have evaluated the feasibility of an outpatient\u2010based combination of vinorelbine and gemcitabine with filgrastim support (VGF) in patients with advanced lymphoma.<\/jats:p><jats:p><jats:bold>Methods: <\/jats:bold> An open\u2010label, single\u2010arm study of 40 consecutive patients with relapsed (<jats:italic>n<\/jats:italic>\u2003=\u200324) or refractory (<jats:italic>n<\/jats:italic>\u2003=\u200316) lymphoma was undertaken. The median number of prior regimens was three (range 1\u201311) and 12 had undergone prior stem cell transplantation. Patients received vinorelbine 25\u2003mg\/m<jats:sup>2<\/jats:sup> and gemcitabine 1000\u2003mg\/m<jats:sup>2<\/jats:sup> on days 1 and 8 of each 21\u2010day cycle. Patients showing no response after two cycles (early response) were offered alternative therapy. Responding patients received two more cycles. Primary end\u2010points were the early and overall response rates.<\/jats:p><jats:p><jats:bold>Results: <\/jats:bold> One hundred and sixteen cycles of therapy were delivered. Hospital admissions were required following 27 treatment cycles (24%), predominantly following cycle 1. Febrile neutropenia followed 6% of cycles. The early and overall response rates on an intention\u2010to\u2010treat basis were 60 and 53%, respectively. Responses for peripheral T\u2010cell lymphoma and Hodgkin lymphoma were particularly encouraging, 70 and 75%, respectively. With a median follow up of 34\u2003months overall survival for the entire cohort at 2\u2003years is 50%. Furthermore, for the 23 patients who did not receive high\u2010dose consolidative therapy 2\u2010year survival was 35%.<\/jats:p><jats:p><jats:bold>Conclusions: <\/jats:bold> Vinorelbine and gemcitabine with filgrastim support can be safely delivered in an outpatient setting and shows clinically meaningful activity against a range of advanced lymphoma subtypes.<\/jats:p>","DOI":"10.1111\/j.1445-5994.2007.01397.x","type":"journal-article","created":{"date-parts":[[2007,6,2]],"date-time":"2007-06-02T07:09:46Z","timestamp":1180768186000},"page":"760-766","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Pilot study of an outpatient\u2010based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim"],"prefix":"10.1111","volume":"37","author":[{"given":"A","family":"Spencer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Reed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Arthur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,6,2]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)92020-I"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910540413"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70471-8"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)92411-L"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512073332305"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.023"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V71.1.117.117"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199909145738"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3776"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199909058430"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199909058458"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428199909169617"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1069(199809)16:3<101::AID-HON629>3.0.CO;2-#"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3786"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2004.n.017"},{"key":"e_1_2_5_17_2","first-page":"15","article-title":"Experimental antitumor activity of Navelbine","volume":"16","author":"Cros S","year":"1989","journal-title":"Semin Oncol"},{"key":"e_1_2_5_18_2","first-page":"3","article-title":"Gemcitabine: pre\u2010clinical pharmacology and mechanisms of action","volume":"23","author":"Plunkett W","year":"1996","journal-title":"Semin Oncol"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006136112585"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_5_21_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/annonc\/mdg703","article-title":"Outpatient\u2010based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant\u2010eligible patients with non\u2010Hodgkin\u2019s lymphoma and Hodgkin\u2019s disease","volume":"14","author":"Hertzberg M","year":"2003","journal-title":"Ann Oncol"},{"key":"e_1_2_5_22_2","first-page":"707","article-title":"Assessing and managing venous irritation associated with vinorelbine tartrate","volume":"22","author":"Rittenberg CN","year":"1995","journal-title":"Oncol Nurs Forum"},{"key":"e_1_2_5_23_2","first-page":"225","article-title":"[Prophylaxis of toxic effects on the peripheral venous system associated with intravenous administration of vinorelbine","volume":"150","author":"Cinieri S","year":"1999","journal-title":"Clin Ter"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s005200000190"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1080\/08880010490272975"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2005.00482.x"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-005-1082-9"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500312295"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20587"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602514"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02743.x"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.13.2603"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.13.2615"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg496"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04226.x"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.coc.0000144812.74663.d0"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02795.x"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1445-5994.2007.01397.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1445-5994.2007.01397.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T17:07:11Z","timestamp":1697389631000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1445-5994.2007.01397.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,2]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["10.1111\/j.1445-5994.2007.01397.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1445-5994.2007.01397.x","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,2]]},"assertion":[{"value":"2007-06-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}